**Supplementary Table 1. Univariate, age and gender adjusted and, multivariate1 adjusted predictors for adalimumab trough level**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Body composition areas** | **Adalimumab only (n=25)** | | | | | |
| **Unadjusted** | **p-value** | **Age- and gender-adjusted** | **p-value** | **Multivariate regression** | **p-value** |
| **Abdominal Circumference** | -0.07 (-0.21, 0.07) | 0.29 | -0.11 (-0.31, 0.09) | 0.26 | -0.06 (-0.26, 0.13) | 0.52 |
| **Visceral Fat Area** | -0.01 (-0.03, 0.01) | 0.21 | -0.01 (-0.04, 0.01) | 0.27 | -0.005 (-0.04, 0.03) | 0.74 |
| **Subcutaneous Fat Area** | -0.01 (-0.03, 0.02) | 0.64 | -0.01 (-0.04, 0.01) | 0.25 | -0.004 (-0.03, 0.02) | 0.70 |
| **Total fat area** | -0.01 (-0.02, 0.01) | 0.32 | -0.01 (-0.02, 0.01) | 0.20 | -0.003 (-0.02, 0.01) | 0.68 |
| **Skeletal Muscle Area** | -0.02 (-0.07, 0.03) | 0.39 | 0.003 (-0.06, 0.07) | 0.93 | -0.03 (-0.09, 0.04) | 0.42 |
| **Visceral Fat Area corrected for Stature** | -0.03 (-0.08, 0.03) | 0.29 | -0.04 (-0.12, 0.04) | 0.31 | -0.005 (-0.10, 0.09) | 0.91 |
| **Skeletal Muscle Area corrected for Stature** | -0.03 (-0.20, 0.14) | 0.69 | 0.03 (-0.2, 0.22) | 0.77 | -0.03 (-0.22, 0.17) | 0.79 |
| **VFA/SMA** | -1.26 (-3.85, 1.33) | 0.33 | -1.80 (-5.23, 1.62) | 0.29 | 0.07 (-4.31, 4.44) | 0.97 |
| **Body mass index in kg/m2** | -0.11 (-0.44, 0.23) | 0.52 | -0.15 (-0.54, 0.25) | 0.45 | -0.03 (-0.42, 0.35) | 0.85 |
| 1Multivariate regression adjustment for age, sex, C reactive protein (mg/ml), albumin (g/L), antibody seropositivity ((>100 IU/ml), concurrent immunomodulator use (thiopurines of methotrexate). | | | | | | |